ORIGINAL ARTICLE
TERT promoter mutation and proEx C are useful as a screening tool to predict the malignant behavior of thyroid tumors of uncertain malignant potential
1
Pathology Department, Faculty of Medicine, Zagazig University, Egypt
2
Otorhinolaryngology Department, Faculty of Medicine, Zagazig University, Egypt
3
General Surgery Department, Faculty of Medicine, Zagazig University, Egypt
4
Histology and Cell Biology Department, Faculty of Medicine, Tanta University, Egypt
Submission date: 2020-08-07
Acceptance date: 2020-10-06
Publication date: 2021-02-22
Pol J Pathol 2020;71(4):314-327
KEYWORDS
TOPICS
ABSTRACT
Gray zone thyroid tumors for which benignity or malignancy cannot be assessed are constantly increasing and accurate prediction of their malignant behavior is vital to avoid both violent surgical intervention for benign tumors and lax treatment of malignant tumors. The retrospective study included 120 blocks of thyroid lesions; 60 patients underwent partial thyroidectomy for query atypical adenoma and 60 blocks of complementary thyroidectomy of the same patients. Complementary thyroidectomy blocks included 21cases of thyroid cancer and 39 cases were multinodular goiter, while partial thyroidectomy blocks included 15 cases of thyroid adenoma, 17 cases were colloid nodules and 28 cases were tumors of uncertain malignant potential (TUMP). The expression levels of both telomerase reverse transcriptase (TERT) promoter mutations and proEx C antibodies were assessed in all blocks; analysis and correlation of marker expression of both groups (complementary and partial thyroidectomy) were done. 20 patients out of 28 suffering from TUMP developed thyroid carcinoma. Ten of them had positive TERT promoter mutation, all of which turned into cancer thyroid in a mean time of 8.2 ±2.61 years, and seventeen who a had high proEx C labeling index (LI) underwent a malignant transformation in 7.52 ±1.17 years in a shorter time than the group with negative TERT/proEx C expression which transformed within 12.31 ±3.57 years, whereas only one case diagnosed first as thyroid adenoma transform into thyroid carcinoma. TERT promoter mutation and proEx C expression are promising markers for determining the malignant potential in tumors of uncertain malignant potential.
REFERENCES (39)
1.
Papotti M, Rodriguez J, De Pompa R, et al. Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Mod Pathol 2005; 18: 541-546.
2.
Williams ED, Group CP. Guest editorial: two proposals regarding the terminology of thyroid tumors. Sage Publications Sage CA, Thousand Oaks, CA 2000.
3.
Yassin Fel-Z. Diagnostic criteria of well differentiated thyroid tumor of uncertain malignant potential; a histomorphological and immunohistochemical appraisal. J Egypt Natl Canc Inst 2015; 27: 59-67.
4.
Lam AK-Y. Pathology of endocrine tumors update: World Health Organization new classification 2017 – other thyroid tumors. AJSP Rev Rep 2017; 22: 209-216.
5.
Liu Z, Zhou G, Nakamura M, et al. Encapsulated follicular thyroid tumor with equivocal nuclear changes, so-called well-differentiated tumor of uncertain malignant potential: a morphological, immunohistochemical, and molecular appraisal. Cancer Sci 2011; 102: 288-294.
6.
Daniel M, Peek GW, Tollefsbol TO. Regulation of the human catalytic subunit of telomerase (hTERT). Gene 2012; 498: 135-146.
7.
Liu T, Yuan X, Xu D. Cancer-specific telomerase reverse transcriptase (TERT) promoter mutations: biological and clinical implications. Genes (Basel) 2016; 7: 38.
8.
Huang DS, Wang Z, He XJ, et al. Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. Eur J Cancer 2015; 51: 969-976.
9.
Alsabbagh A, Robins TL, Harriman A, et al. Surrogate markers for high-risk human papillomavirus infection in oral epithelial dysplasia: A comparison of p16, Ki-67, and ProExC. Oral Surg Oral Med Oral Pathol Oral Radiol 2020; 129: 246-259.e1.
10.
Badr RE, Walts AE, Chung F, et al. BD ProEx C: a sensitive and specific marker of HPV-associated squamous lesions of the cervix. Am J Surg Pathol 2008; 32: 899-906.
12.
and telomerase expression in papillary thyroid carcinomas. Eur J Surg Oncol 2004; 30: 73-79.
13.
Mar KC, Eimoto T, Nagaya S, et al. Cell proliferation marker MCM2, but not Ki67, is helpful for distinguishing between minimally invasive follicular carcinoma and follicular adenoma of the thyroid. Histopathology 2006; 48: 801-807.
14.
Kearsey SE, Maiorano D, Holmes EC, et al. The role of MCM proteins in the cell cycle control of genome duplication. Bioessays 1996; 18: 183-190.
15.
Lei M, Tye BK. Initiating DNA synthesis: from recruiting to activating the MCM complex. J Cell Sci 2001; 114: 1447-1454.
16.
Tan D-F, Huberman JA, Hyland A, et al. MCM2-a promising marker for premalignant lesions of the lung: a cohort study. BMC Cancer 2001; 1: 1-7.
17.
Liu X, Bishop J, Shan Y, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer 2013; 20: 603-610.
18.
Al-Rejaie SS, Aleisa AM, Sayed-Ahmed MM, et al. Protective effect of rutin on the antioxidant genes expression in hypercholestrolemic male Westar rat. BMC Complement Altern Med 2013; 13: 1-9.
19.
Kakudo K. How to handle borderline/precursor thyroid tumors in management of patients with thyroid nodules. Gland Surg 2018; 7 (Suppl 1): S8-S18.
20.
Khatami F, Tavangar SM. A review of driver genetic alterations in thyroid cancers. Iran J Pathol 2018; 13: 125-135.
21.
Zhang YY, Liu ZB, Ye XG, et al. Iodine regulates G2/M progression induced by CCL21/CCR7 interaction in primary cultures of papillary thyroid cancer cells with RET/PTC expression. Mol Med Rep 2016; 14: 3941-3946.
22.
Goodhead Dt. Initial events in the cellular effects of ionizing radiations: clustered damage in DNA. Int J Radiat Biol 1994; 65: 7-17.
23.
Duan H, Liu X, Ren X, et al. Mutation profiles of follicular thyroid tumors by targeted sequencing. Diagn Pathol 2019; 14: 39.
24.
Nese N, Gupta R, Bui MH, et al. Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis. J Natl Compr Canc Netw 2009; 7: 48-57.
25.
Hofman V, Lassalle S, Bonnetaud C, et al. Thyroid tumours of uncertain malignant potential: frequency and diagnostic reproducibility. Virchows Arch 2009; 455: 21-33.
26.
Guerra A, Carrano M, Angrisani E, et al. Detection of RAS mutation by pyrosequencing in thyroid cytology samples. Int.
28.
Medici M, Kwong N, Angell TE, et al. The variable phenotype and low-risk nature of RAS-positive thyroid nodules. BMC Med 2015; 13: 184.
29.
Medici M, Liu X, Kwong N, et al. Long-versus short-interval follow-up of cytologically benign thyroid nodules: a prospective cohort study. BMC Med 2016; 14: 11.
30.
Durante C, Costante G, Lucisano G, et al. The natural history of benign thyroid nodules. JAMA 2015; 313: 926-935.
31.
Xing M. Clinical utility of RAS mutations in thyroid cancer: a blurred picture now emerging clearer. BMC Med 2016; 14: 1-4.
32.
Liu R, Xing M. TERT promoter mutations in thyroid cancer. Endocr Relat Cancer 2016; 23: R143-R155.
33.
Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 2013; 13: 184-199.
34.
Giordano TJ, Kuick R, Thomas DG, et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 2005; 24: 6646-6656.
35.
Agrawal N, Akbani R, Aksoy BA, et al. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014; 159: 676-690.
36.
Bae J-S, Choi SK, Jeon S, et al. Impact of NRAS mutations on the diagnosis of follicular neoplasm of the thyroid. Int J Endocrinol 2014; 2014: 289834.
37.
Hysek M, Paulsson JO, Wang N, et al. TERT promoter mutational screening as a tool to predict malignant behaviour in follicular thyroid tumours – three examples from the clinical routine. Virchows Arch 2018; 473: 639-643.
38.
Paulsson JO, Mu N, Shabo I, et al. TERT aberrancies: a screening tool for malignancy in follicular thyroid tumours. Endocr Relat Cancer 2018; 25: 723-733.
39.
Tosuner Z, Türkmen I, Arici S, et al. Immunocytoexpression profile of ProExC in smears interpreted as ASC-US, ASC-H, and cervical intraepithelial lesion. J Cytol 2017; 34: 34-38.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
